• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

arGEN-X

edit

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.

Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Milestones

edit

• 
  arGEN-X received $36.9M (€27.5M) in Series B funding. (12/1/11)
  Posted 12/1/11 at 5:11am via finsmes.com
• 
  arGEN-X received $4.5M in Series A funding. (2/11/10)
  Posted 2/15/10 at 6:25pm via onbiovc.com
• 
  arGEN-X received $13.6M in Series A funding. (9/10/09)
  Posted 9/14/09 at 6:17am via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. arGEN-X gins $13.6M in new funds for mAB work (fiercebiotech.com) [edit]
2. arGEN-X, BV: Series A $4.5M (onbiovc.com) [edit]
3. arGEN-X Closes €27.5M Series B Funding Round (finsmes.com) [edit]